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Background: Targeted lung denervation (TLD) is a novel bronchoscopic therapy for COPD 
which ablates parasympathetic pulmonary nerves running along the outside of the two main 
bronchi with the intent of inducing permanent bronchodilation. The goal of this study was to 
evaluate the feasibility and long-term safety of bilateral TLD during a single procedure.
Patients and methods: This prospective, multicenter study evaluated 15 patients with 
moderate-to-severe COPD (forced expiratory volume in 1 s [FEV
1
] 30%–60%) who underwent 
bilateral TLD treatment following baseline assessment without bronchodilators. The primary 
safety end point was freedom from documented and sustained worsening of COPD directly 
attributable to TLD up to 1 year. Secondary end points included technical feasibility, change 
in pulmonary function tests, exercise capacity, and health-related quality of life. Follow-up 
continued up to 3 years for subjects who reconsented for longer-term follow-up.
Results: A total of 15 patients (47% male, age 63.2±4.0 years) underwent TLD with a total 
procedure time of 89±16 min, and the total fluoroscopy time was 2.5±2.7 min. Primary safety 
end point of freedom from worsening of COPD was 100%. There were no procedural compli-
cations reported. Results of lung function analysis and exercise capacity demonstrated similar 
beneficial effects of TLD without bronchodilators, when compared with long-acting anticho-
linergic therapy at 30 days, 180 days, 365 days, 2 years, and 3 years post-TLD. Five of the 12 
serious adverse events that were reported through 3 years of follow-up were respiratory related 
with no events being related to TLD therapy.
Conclusion: TLD delivered to both lungs in a single procedure is feasible and safe with few 
respiratory-related adverse events through 3 years.
Keywords: COPD, bronchoscopy, radiofrequency ablation, denervation, device
Introduction
COPD is a global health issue.1–3 Academia and industry responded with the 
development of various inhaled therapeutics, but a plateau in treatment effect seems 
to have been reached.4 Therapeutic procedures that provide durable improvements 
in COPD patients are rare, but they are a next logical bridge in the treatment of this 
chronic and progressive disease. However, just as with pharmaceuticals, early safety 
evaluation of devices must first be undertaken to understand long-term effects prior 
to moving into larger efficacy clinical trials.
Targeted lung denervation (TLD) is a novel bronchoscopic therapy for COPD that 
is intended to achieve bronchodilation via ablation of parasympathetic pulmonary 
nerves entering the lung and running along the outside of the two main bronchi. An 
earlier study established a reasonable safety profile when treating both lungs in a staged 
fashion.5 The current study was specifically designed to understand the safety profile 
when completing TLD treatment in both lungs when performed as a single procedure. 
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Investigators hypothesized that this would be the preferred 
way to treat in the future and would result in added safety 
over treatment staging, mainly due to reduced exposure to 
anesthesia and reduced risk of exacerbations induced by 
bronchoscopy. Furthermore, the current study provides 
3-year follow-up data in treated patients to provide early 
information on potential long-term effects of TLD.
Patients and methods
study design
This nonrandomized, prospective single-dose registry study 
was conducted at four sites in Austria (1 site) and France 
(3 sites) between September 6, 2012 and May 5, 2015. This 
design was identical to the previous study5 except that TLD 
therapy was delivered to both lungs during a single procedure 
(vs staged), a single power (vs two) was investigated, and 
additional bronchoscopic and computed tomography (CT) 
assessments at 365 days were conducted to assess safety. Sites 
did not overlap with the previous published first-in-human 
study, which helped to strengthen the safety assessment and 
gain additional user information for device development.
study participants
Major entry criteria were identical to the first-in-human study 
and are listed in Table 1. Follow-up bronchoscopy and CT 
scans were performed to evaluate the longer-term safety of 
treatment areas.
study oversight
This study was approved by the ethics committee of the City 
of Vienna (reference: EC 11-251-0112) and the institutional 
Table 1 Protocol’s inclusion and exclusion criteria
Patient selection criteria
Inclusion criteria
•	 Post-bronchodilator FeV1 30%–60%
•	 Patient is diagnosed with COPD (post-bronchodilator FeV1/FVC,0.7)
•	 Positive relative change in FeV1 of .15% following the administration of ipratropium (MDI with four puffs at 20 µg)
•	 age $40 years
•	 smoking history of at least 10 pack-years
•	 nonsmoking for a minimum of 6 months prior to consent and agreed to continue not smoking for the duration of the study
•	 Patient has provided written informed consent
•	 The patient is willing, able, and agreed to complete all protocols required for baseline and follow-up assessments including taking and abstaining 
from medications
•	 The patient has no child-bearing potential or a negative pregnancy test
•	 Patient is a candidate for bronchoscopy in the opinion of the physician or per hospital guidelines
•	 Current influenza vaccination and/or pneumococcus vaccination consistent with local recommendations and/or policy
Exclusion criteria
•	 Pulmonary hypertension, peripheral edema suggesting ChF or polycythemia
•	 Patient has an saO2#88% or a PaO2#7.3 kPa (55 mmhg)
•	 Patient has a PaCO2.8.0 kPa (60 mmhg)
•	 Prior lung transplant, lVrs, median sternotomy, bullectomy, or lobectomy
•	 Pulmonary nodule requiring surgery
•	 history of recurrent respiratory infections (.3 hospitalizations within 1 year of consent)
•	 Presence of a pacemaker, internal defibrillator, or other implantable electronic devices
•	 active respiratory infection within the past 4 weeks
•	 COPD exacerbation within the past 4 weeks
•	 Myocardial infarction within the past 6 months
•	 Unstable or life-threatening arrhythmia within the past year
•	 Malignancy treated with radiation or chemotherapy within the past 2 years
•	 Presence of other respiratory diseases (cystic fibrosis, tuberculosis, vocal cord dysfunction, Churg-Strauss syndrome, allergic bronchopulmonary 
aspergillosis)
•	 Known hypersensitivity to anticholinergic drugs or components
•	 Known allergy to medications required for bronchoscopy (such as lidocaine and atropine) that cannot be medically controlled
•	 Clinical diagnosis of sleep apnea
•	 Clinical diagnosis of asthma or other respiratory disease other than COPD
•	 Known coagulopathy
•	 Patient is taking clopidogrel, coumadin, or other blood-thinning medication
•	 The patient has any disease or condition that might interfere with completion of this study (eg, life expectancy ,1 year)
•	 Patient is currently enrolled in another clinical trial
Abbreviations: ChF, congestive heart failure; FeV1, forced expiratory volume in 1 s; FVC, forced vital capacity; lVrs, lung volume reduction surgery; MDI, metered-dose 
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safety of bilateral targeted lung denervation
review board (IRB) of South East V, University Hospital 
Center Grenoble (France), Committee for patient protection 
(reference: 2012-A00728-35) and was conducted according 
to the Declaration of Helsinki (1996), Good Clinical Practice 
guidelines, and local requirements. Operations and a data-
monitoring committee oversaw protocol management and 
safety for the study. An independent clinical event reviewer 
adjudicated all reported serious adverse events (SAEs). All 
participating subjects provided written informed consent.
Procedures
Analysis included spirometry, body plethysmography, 
cycle ergometry, 6-min walk test (6MWT), COPD-specific 
St George’s Respiratory Questionnaire (SGRQ, score range 
0–100 with a minimally clinically important difference of $4 
negative units),6 the Clinical SGRQ-C (COPD) (7-day version, 
score range 0–6, with an minimally clinically important differ-
ence of 0.4 units),7 and the common Borg and modified Medical 
Research Council8 scales. All appropriate permissions to use 
validated questionnaires were obtained by the study sponsor. 
Cycle ergometry was first conducted as an incremental maxi-
mal test to determine the baseline maximum work rate (W
max
) 
off drugs and subsequently as an endurance test conducted at a 
constant work rate of 75% of the W
max
.9 The current American 
Thoracic Society/European Respiratory Society (ATS/ERS) 
guidelines were followed for pulmonary function test (PFT);10,11 
however, due to the feasibility nature of the study, no pro-
spective PFT quality oversight program was implemented. 
ATS/American College of Chest Physicians (ACCPs) and 
ATS guidelines were followed for cycle ergometry12 and the 
6MWT,13 respectively. Chest CT scan was required to confirm 
appropriate bronchial anatomy and rule out other pulmonary 
abnormalities prior to treatment and to evaluate bronchial and 
peri-bronchial effects following treatment.
Following informed consent, patients underwent “wash-
out” baseline analysis after a washout period of 8 days for 
long-acting muscarinic antagonists (LAMAs), 24 h for 
long-acting beta agonist (LABA), and 12 h for short-acting 
beta agonist (SABA) and short-acting muscarinic antago-
nist (SAMA). Patients were then asked to take tiotropium 
bromide, and after a minimum of an 8-day run-in period 
similar analysis was performed on drug trough 24 h after 
the last dose of tiotropium to establish “tiotropium trough” 
baseline values. LABAs were again withheld for 24 h and 
SABAs and SAMAs for 12 h prior to this analysis if taken. 
Post-treatment, subjects were asked to remain off tiotropium. 
Similar to the abovementioned information, any COPD 
medications taken by the patient must have been appropri-
ately washed out (based on half-life of the drug) prior to the 
follow-up analysis visits. Paper diaries were utilized by the 
site study coordinators to help manage medications prior to 
analysis. Detailed medication utilization was not tracked as 
part of this feasibility study.
All patients underwent early safety evaluation by phone 
at 3 and 10 days post-procedure and analysis at washout 
baseline, tiotropium trough baseline, and 30, 90, 180, 270, 
and 365 days, and then 1.5, 2, 2.5, and 3 years post-treatment 
if reconsented for longer-term follow-up. Exceptions to the 
analysis schedule was cycle ergometry that was performed 
only at washout baseline, 90, 180, and 365 days, and 2 years 
following treatment; bronchoscopy was performed at treat-
ment and 90 and 365 days post-procedure; CT scan was 
performed at washout and 365 days after treatment.
TlD
TLD was delivered via a dual cooled radiofrequency 
(RF) generator system (Figure 1) and has been previously 
described.5
As RF current is delivered through the airway and sur-
rounding tissues, these tissues are heated and the nerves are 
ablated. Simultaneous cooling removes heat from the inner 
surface of the bronchi. The net effect is the targeted tissue 
ablation at depth with minimal heating and damage of the 
inner surface of the airway. The goal of targeted ablation is to 
disrupt motor axons within bronchial nerve branches running 
along the main bronchi, thereby blocking parasympathetic 
signaling to the lungs and decreasing neuronal release of 
acetylcholine (Figure 2).
TLD was performed under general anesthesia via rigid 
bronchoscopy due to the dimensions of this first-generation 
catheter. The study was designed to assess the safety of 
bilateral lung treatment during a single procedure; however, 
a procedure could be staged per physician discretion. The 
electrode was placed and activated as prescribed in up to 
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eight rotational positions per bronchus to achieve a complete 
circumferential treatment. Bronchoscopic and fluoroscopic 
visualization was used to guide in electrode positioning. 
Energy-level determination came from extensive preclinical 
analysis and early safety outcomes from the first-in-human 
study.5 Subjects were asked to stop taking tiotropium after 
the completion of the procedure.
study end points
The primary safety end point of freedom from documented 
and sustained worsening of COPD directly attributable to the 
investigational device or procedure to 365 days post-TLD 
therapy was defined as a decrease in the individual patient’s 
forced expiratory volume in 1 s (FEV
1
) by any amount at all 
follow-up time points along with a report of an adverse event 
that was reported to have a probable or definite relation to the 
device. Secondary end points included technical feasibility of 
the device, change in PFTs, exercise capacity assessments, 
and health-related quality of life. Technical feasibility was 
defined as the ability to access the target treatment area in the 
main bronchus and deliver RF energy to the entire circumfer-
ence of the bronchus at the target treatment sites.
statistical analyses
There was no primary study hypothesis with statistical infer-
ence for the small registry study. All p-values were presented 
for informational purposes. According to the prespecified 
analysis plan, continuous data were summarized using mean 
and SD, or medians and quartiles in the presence of non-
normality. Categorical data were tabulated with counts and 
percentages. All the available data were summarized with no 
imputation for missing data. Final analyses were conducted 
using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) 
by an independent statistical group (NAMSA, Minneapolis, 
MN, USA).
Results
Baseline characteristics for the 15 patients treated are shown 
in Table 2. Patient disposition throughout 3 years is shown 
in Figure 3. Follow-up data beyond 365 days were available 
for 67% (n=10) at 2 years and 60% (n=9) at 3 years. Three 
patients did not participate in follow-up beyond 1 year and 
refused or withdrew consent, with one withdrawing due to 
planned bladder surgeries. Later study exits were due to 
physician discretion and relocation.
Technical success of TLD treatment was achieved in 
93% of cases, with one patient receiving treatment in seven 
of eight expected quadrants due to poor balloon contact. No 
device-related adverse events during the procedure were 
reported. All 15 patients underwent treatment at an energy 







Figure 2 representative ablation procedure. 
Notes: (A) Image of a representative ablation. The catheter is in left bronchus with 
electrode in the lateral position. Catheter is rotationally repositioned to achieve 
complete circumferential treatment. Both the catheter and electrode are filled 
with cooled fluid to protect the airway inner surface during ablation. (B) Blue lines 
designate the area of circumferential ablation in main bronchi. attenuation of nerve 
fibers along the outside of the airway is represented by change in color.
Table 2 Baseline characteristics
Characteristics n=15
age (years) 63.20 (3.97)
Male, n (%) 7 (47)
ethnic origin, n (%)
White 15 (100)
history of smoking, n (%) 15 (100)
Pack-years 39.4 (6.16)
Washout pre-bronchodilator FeV1 (l) 0.77 (0.24)*
Washout pre-bronchodilator FeV1 (%) 28.6 (10.9)*
Washout pre-bronchodilator FVC (l) 2.25 (0.61)*
reversibility peak relative change in FeV1 (%) 38.01 (20.18)
run-in tiotropium trough, FeV1 (l) 1.09 (0.22)
run-in tiotropium trough, FVC (l) 2.70 (0.73)
average diameter: right main bronchus (mm)** 14.10 (2.74)
average diameter: left main bronchus (mm)** 13.15 (1.69)
Notes: Data are represented as mean (sD) unless stated otherwise. *Post-
bronchodilator information not correctly recorded in error. **Measurements by 
sponsor using apollo® software (VIDa Diagnostics, Coralville, Ia, Usa). 
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safety of bilateral targeted lung denervation
two patients due to the airway size being unexpectedly larger 
than the balloon available at the time of the initial treatment.
safety
The primary safety end point, defined as freedom from docu-
mented and sustained worsening of COPD directly attribut-
able to the investigational device or procedure to 365 days 
post-TLD therapy, was achieved in 100% (15/15) of patients. 
No significant wall effects (ie, ulcers and narrowing) were 
observed during this study at either the 90-day or 365-day 
follow-up bronchoscopy and CT assessments (Figure 4).
No device-related adverse events were reported. No 
deaths occurred in the entire 3-year follow-up period. A total 
of 12 SAEs were reported during the follow-up consisting 
of five COPD exacerbations (occurring at 3 months, 1 year, 
1.5 years, and 2 at 2 years), one urinary retention (with diffi-
cult Foley catheter placement and sequela of benign prostatic 
hypertrophy) occurring 30 days post-treatment, one wors-
ening of an underlying arrhythmia 85 days post-treatment, 
one hemoptysis (negative bronchoscopy and suspected 
epistaxis), one motorcycle accident at 24 months, one tran-
sient ischemic attack between 2 and 3 years post-treatment, 
and one nonfatal stroke between 2 and 3 years (Table 3).
lung function, exercise capacity, 
and quality of life
To understand the impact of TLD alone on efficacy measures, 
















Figure 3 subject disposition.
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Figure 4 example of acute and follow-up CT and airway safety inspections.






Table 3 summary of adverse events through 3 years
Adverse event #30-day events 
(n=15), n (%)







COPD exacerbation 2 (13) 3 (30)
heart arrhythmia 1 (7)
hemoptysis 1 (10)
hypertrophy of prostate 1 (7)
Motorcycle accident 1 (11)
stroke 2 (22)
Urinary retention 1 (7)
nonserious adverse events
Common cold 1 (7)
COPD exacerbation 2 (13) 2 (13) 11 (110) 3 (33)
Cough 1 (7)
Dislodged teeth 1 (7)
Dysphagia 2 (13)
epigastric pain 2 (13)
headache 1 (11)
hemoptysis 1 (7) 1 (10)
herpes zoster 1 (10)
hoarseness 1 (11)
hypoxemia 1 (7)
lower respiratory infection 5 (33) 1 (10)
nausea/vomiting 1 (7)
Paresthesia (left hand) 1 (10)
Tachycardia 2 (22)
Tingling in left upper lobe 1 (7)
Thoracic pain 1 (7)
sigmoiditis 1 (7)
syncope 1 (11)
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safety of bilateral targeted lung denervation
bronchodilators, if taken, as previously described. There 
were statistically significant improvements in lung func-
tion and exercise capacity at 365 days post-TLD treatment 
(Table 4).
Improvements observed for percent relative change com-
pared with washout baseline of FEV
1
 were significant at all 
follow-up time points throughout 365 days and for forced 
vital capacity (FVC) at 30 (p=0.017), 180 (p=0.016), and 
365 days (p=0.024; Figure 5). Changes in 6MWT reached 
statistical significance at 90 ( p=0.015) and 365 days 
(p=0.014) post-TLD treatment. No statistical significance 
was noted in SGRQ-C changes. Despite numerically higher 
FEV
1
 and FVC values at 2 and 3 years, statistical significance 
was lost for parameters of lung function and exercise capacity 
at these longer follow-up visits.
Discussion
Bilateral TLD therapy performed in a single session in this 
study demonstrated acceptable peri- and post-procedural 
safety up to 3 years.
Interruption of vagal innervation to the lung may diminish 
acetylcholine release from these nerves, which in turn has an 
influence on airway smooth muscle tone, mucus secretion, 
and/or local inflammatory processes throughout the bronchial 
tree.14 Indeed, pharmacologic blockade of vagal innervation 
has been shown to produce sustained bronchodilation and a 
decrease in mucus production.15 An alternative, yet high risk, 
path of vagal denervation would be surgical resection of the 
airway nerve trunks of the vagus nerves in human subjects, 
which according to previous reports led to significant lung 
function improvements in patients with chronic airflow 
Figure 5 Secondary efficacy end points.
Notes: Yellow line represents timing of TlD procedure. Data are represented as mean. error bars represent seM. all measures compared with washout baseline analysis. 
*p,0.05 compared with baseline.
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Baseline 365 days Percent change 
from baseline
FeV1 (ml) 765.33 (237.45) 1,012.14 (272.99) 40.29 (42.12)*
FVC (ml) 2,248.00 (614.05) 2,605.00 (634.59) 19.25 (24.84)*




7.36 (2.96) 9.81 (4.92) 2.68 (6.06)
Borg scale: post-
cycle dyspnea
5.4 (2.35) 4.64 (1.21) -0.82 (1.83)
mMrC 2.27 (1.03) 1.60 (1.06) -0.67 (1.05)
6MWT (m) 361.8 (125.62) 415.47 (112.76) 53.67 (74.40)*
sgrQ: total score 47.95 (16.97) 49.37 (20.93) -1.85 (20.77)
CCQ: total score 2.71 (1.17) 2.63 (1.41) 0.00 (1.29)
Notes: Data are represented as mean (sD) unless stated otherwise. *p,0.05 
compared with baseline.
Abbreviations: CCQ, Clinical COPD Questionnaire; FeV1, forced expiratory 
volume in 1 s; FVC, forced vital capacity; mMRC, modified Medical Research 
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obstruction.16–18 TLD is a novel bronchoscopic therapy that, 
using a minimally invasive approach, ablates the parasym-
pathetic innervation of the lungs and has a similar proposed 
mechanism of action to surgical denervation, albeit with the 
potential of lower morbidity and mortality.19 TLD therapy 
ablates airway nerve trunks using predetermined RF energy 
while minimizing damage to tissues of the main bronchi 
through the use of a dual cooling method. We have previ-
ously reported results from the first-in-human feasibility and 
safety study of TLD using a sequential, bilateral treatment 
approach. In that report, TLD was associated with a higher 
SAE rate of 1.4 events per patient (31 SAEs in 22 patients) 
up to a follow-up of 1 year. In the current study, patients 
with similar baseline characteristics experienced an aver-
age 3-year SAE rate of 0.26 per patient/year (12 SAEs in 
15 patients), which may indicate improved safety by utilizing 
the bilateral approach and lower delivered energy as well 
as advancements in overall procedural training over time.5 
In fact, in the current study, the procedure was consistently 
modified to more distal electrode placement away from 
the thin and thermally sensitive main carina, more detailed 
visual assessment of balloon contact before activation, and 
a decrease in overall power to 15 W to further reduce the 
potential for undesired airway wall effects. In this context, 
the overall low rate of severe COPD exacerbations during 
the follow-up period of up to 3 years appears noteworthy. 
In the absence of a control group, we cannot rule out that 
this observation is due to a recruitment bias rather than the 
above-discussed anticholinergic pleiotropic effects, which 
may influence exacerbation rates similar to pharmacologi-
cal acetylcholine blockade. Furthermore, given the potential 
impact of vagotomy on cardiovascular autonomic tone,20 it 
should be noted that there was no evidence of an increased 
risk of cardiac events associated with the TLD procedure in 
the current study.
Noteworthy, lung function improvements after TLD 
therapy at 1 year observed in the current study were of similar 
magnitude to results from the high-energy cohort (20 W) but 
higher than the low-energy cohort (15 W) in our previous 
study.5 The latter observation may be explained by an overall 
higher peak reversibility response to ipratropium on FEV
1
 at 
baseline in the current study cohort (38%) compared with a 
reversibility peak relative change in FEV
1
 between 20% and 
26% in the previous study. This selection bias may further 
explain the relatively large magnitude of tiotropium effect 
during the washout and run-in analysis procedures observed. 
While the predictive ability of the acute bronchodilator 
response to long-term inhaled anticholinergic therapy is 
limited, our observation may indicate a relationship between 
the response to inhaled short-acting anticholinergic therapy 
and effects of permanent vagal denervation using TLD 
therapy. We should acknowledge, however, that the absence 
of acute bronchodilator response at one occasion may not 
preclude the demonstration of bronchodilator response on 
another occasion,21 thus limiting the overall usefulness of 
this criterion for future patient selection for TLD therapy. 
Another potential explanation for the differences in outcomes 
between the 15 W cohorts is the lower rates of SAEs observed 
in the current manuscript compared with our previous work, 
which may have contributed to an overall better treatment 
response in the absence of clinical events compromising 
potential benefits of TLD.
The current study furthermore demonstrated sustained 
effects of TLD therapy on FEV
1
 and FVC up to 3 years 
compared with baseline. In addition to the bronchodilator 
effect that is expected by reducing the release of acetylcholine 
from the parasympathetic nerves, a previous inflammatory 
marker study has also provided evidence of potentially 
inhibiting inflammation and mucus gene expression with 
TLD therapy.22 This finding is consistent with other studies 
that indicate anti-inflammatory effects of inhaled anticho-
linergic therapy.23,24
While the improvements in lung function were in part 
accompanied by benefits in exercise capacity, they did not 
translate into consistent benefits of health-related quality of 
life in this study. There are a number of potential explana-
tions for this observation as well as other limitations to this 
report. First, the small sample size likely leads to variability 
across the time points assessed and not all patients continued 
follow-up beyond 365 days when the study was extended. 
Second, it has to be acknowledged that there is a rather mod-
est relationship between treatment-related improvements in 
FEV
1
 and health-related quality of life.25 On the other hand, 
we have to acknowledge that in the absence of a control 
group undergoing a sham treatment and the lack of direct 
measurements of therapeutic efficacy of TLD, such as his-
tological proof of denervation in vivo, improvements in lung 
function and exercise capacity observed in the current study 
may have been an intervention effect, rather than a result 
of the intended mechanism of action. Given the magnitude 
of response with respect to the FEV
1
 demonstrated in this 
study and a strict inhaler washout procedure prior to lung 
function measurements, however, there is a high likelihood 
of an independent treatment effect.
With long-term safety of TLD being established between 
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safety of bilateral targeted lung denervation
further refining the procedure, studying potentially additive 
effects of TLD on top of LAMA treatment, and conducting 
careful patient phenotyping analysis to identify those patients 
most likely to benefit from this novel therapy. Since study 
completion, the manufacturer has made significant device 
enhancements which allow replacement of rigid bronchos-
copy with flexible endoscopy and is currently conducting a 
randomized, sham control dose and patient selection opti-
mization study.
Conclusion
This intervention study adds to the early body of evidence 
confirming the feasibility and safety of TLD in patients with 
symptomatic moderate-to-severe COPD.
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